Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients with diabetes. RESEARCH DESIGN AND METHODS: This study includes 193,099 patients in the Kaiser Permanente Northern California diabetes registry who were ≥40 years of age between 1997 and 2002. Those with prior bladder cancer were excluded. Ever use of each diabetes medication (defined as two or more prescriptions within 6 months) was treated as a time-dependent variable. Cox regression–generated hazard ratios (HRs) compared pioglitazone use with nonpioglitazone use adjusted for age, sex, race/ethnicity, diabetes medications, A1C, heart failure, household income, renal function, other bladder conditions, and smoking. RESULTS: The group treated with pioglitazone comprised 30,173 patients. There were 90 cases of bladder cancer among pioglitazone users and 791 cases of bladder cancer among nonpioglitazone users. Overall, ever use of pioglitazone was not associated with risk of bladder cancer (HR 1.2 [95% CI 0.9–1.5]), with similar results in men and women (test for interaction P = 0.8). However, in the a priori category of >24 months of therapy, there was an increased risk (1.4 [1.03–2.0]). Ninety-five percent of cancers diagnosed among pioglitazone users were detected at early stage. CONCLUSIONS: In this cohort of patients with diabetes, short-term use of pioglitazone was not associated with an increased incidence of bladder cancer, but use for more than 2 years was weakly associated with increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Observational research conducted in 2011 and 2012 suggested that pioglitazone may increase the risk of bladder cancer.46,47”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, some data suggest an association between the use of pioglitazone and an increased risk of bladder cancer (191).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Some research suggests that metformin use is associated with a reduced risk for various cancers (23,24); others have suggested that insulin use might increase the risk of cancer (24,25).”
BackgroundDiabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Elstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
Cited by
Items 601–700 of 711
Classification, epidemiology, diagnosis, and risk factors of diabetes
Curtis, J. M., & Knowler, W. C. (2014) · Wiley eBooks · doi:10.1002/9781118887837.ch2
Herbst, L. (2012) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-11667
Tushuizen, M. E. (2012) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Yaturu, S. (2013) · InTech eBooks · doi:10.5772/56419
Les sécrétions du tissu adipeux : rôles de l'autotaxine et recherche de nouvelles adipokines
Dusaulcy, R. (2011) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose
Cao, L., Li, J., Wu, H., Liu, G. J., Dong, B. R., & Lü, Q. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009989
Towards a Health Economic Simulation Model of Type 2 Diabetes in Sweden
Kiadaliri, A. (2014) · Lund University Publications (Lund University)
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Human in vivo studies on the non-glycaemic effects of thiazolidinedione derivatives
Rennings, A. J. M. (2014) · Radboud Repository (Radboud University)
Pharmacotherapy of diabetes and cancer risk
Kaku, K., & Hashiramoto, M. (2011) · Diabetology International · doi:10.1007/s13340-011-0043-x
Dynamic Controversies of Pioglitazone
Laway, B. A., & Kotwal, S. K. (2012) · International Journal of Medicine and Public Health · doi:10.4103/2230-8598.108381
Chandru, S., Janarthanan, V. V., & Mohan, V. (2012) · Indian journal of clinical medicine · doi:10.4137/ijcm.s10505
Editorial. Medicine Shouldn’t Be Considered a Good Business
Ionescu-Tirgoviste, C. (2012) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/v10255-012-0039-8
Pioglitazone for adults with high risk of developing type 2 diabetes mellitus
Cao, L., Sun, H., Wu, H., Lü, Q., & McKee, A. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011759
RetractedExenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors
Htike, Z. Z., Khunti, K., & Davies, M. J. (2012) · Clinical Practice · doi:10.2217/cpr.11.132
Durlach, V. (2011) · Médecine thérapeutique · doi:10.1684/met.2011.0332
Habel, L. A., Ferrara, A. M., Bilker, W. B., Quesenberry, C. P., Selby, J. V., Eeden, S. K. V. D., Strom, B. L., & Lewis, J. D. (2011) · Diabetes Care · doi:10.2337/dc11-0763
Self-citationTreatment with Thiazolidinediones
Suvag, S., Utzschneider, K. M., & Kahn, S. E. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_9
Updates on blood glucose monitoring in patients with diabetes
Hui, E. (2013) · The HKU Scholars Hub (University of Hong Kong)
Prieto-Díaz, M. Á., Escobar, C., & Molinera, V. G. (2014)
Thiazolidinedione, friend or foe?
Sachan, A. (2016) · The Journal of Clinical and Scientific Research · doi:10.15380/2277-5706.jcsr.16.03.002
4. Pioglitazone and Bladder Cancer
Sato, T. S. (2012) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.43.277
ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., & Eldor, R. (2013)
Alves, C. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Pioglitazone Use and Risk of Bladder Cancer
Singh, S., & Suchard, M. A. (2015) · JAMA · doi:10.1001/jama.2015.13912
羽田, 裕., 敏正, 山., & 孝, 門. (2015) · 心臓 · doi:10.11281/shinzo.47.951
FIXED COMBINATION OF ANTIDIABETIC DRUGS IN THE TREATMENT OF TYPE 2 DIABETES: FROM THEORY TO PRACTIC
Karachentsev, Y. I., Kazakov, A., Romanova, I. P., Chernyavska, I. V., & Кравчун, Н. А. (2014) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2014.4.09
Revisión de los tratamientos farmacológicos actuales y futuros de la esteatohepatitis no alcohólica
Akhter, A., Pulla, A., & Said, A. (2016) · Clinical Liver Disease · doi:10.1002/cld.596
Nutzen und Risiken der modernen Pharmakotherapie des Typ-2-Diabetes
Gustav, U. C., Dresden, C., & Wehling, M. (2012)
THE STROMAL ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN BREAST TUMOURIGENESIS
Skelhorne‐Gross, G. (2014) · QSpace (Queen's University Library)
Krentz, A. J., & Sinclair, A. J. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch21
Refinement of the Docking Component of Virtual Screening for PPAR
Lewis, S. N. (2013) · VTechWorks (Virginia Tech)
Glucocorticoid Receptor beta Increases the Migration of Human Urothelial Carcinoma Cells
McBeth, L. (2016) · OhioLink ETD Center (Ohio Library and Information Network)
Diabète de type2: antidiabétiques oraux
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00009-2
Pharmacokinetics and effect of pioglitazone in obese, insulin-resistant cats
Clark, M. (2013) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Aberrant PI3K Signaling Pathway in Urinary Bladder Cancer
Siddiqui, Z. (2017) · International Journal of Cell Science & Molecular Biology · doi:10.19080/ijcsmb.2017.02.555584
Trappiel, M. (2017) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-16744
Dissecting mechanisms involved in the aetiological overlap between Type 2 diabetes and cancer
Pal, A. (2013) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-g71wpror4
Sharma, M., Azharuddin, A., Faheem, T., Adil, M., & Ghosh, P. (2018) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/5/2/001101
Koffert, J. (2018) · UTUPub (University of Turku)
Louiselle, E. (2019) · University of Minnesota Digital Conservancy (University of Minnesota)
Gysling, E. (2011) · pharma-kritik · doi:10.37667/pk.2010.825
Rebola, J. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Large Clinical Trials and Registries—Clinical Research Institutes
Califf, R. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382167-6.00026-6
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Non-viral liver diseases: pathogenetic approaches to therapy
Osadchuk, M. A., & Mironova, E. D. (2019) · Medical alphabet · doi:10.33667/2078-5631-2019-2-20(395)-30-36
Type 2 Diabetes Mellitus: Marketed Drugs and Mechanisms
Misra, P., & Chakrabarti, R. (2021) · Springer eBooks · doi:10.1007/978-981-15-8002-4_7
박상훈 (2014) · Korean Journal of Medicine
COMBINED THERAPY OF TYPE 2 DIABETES IN THE FAMILY DOCTOR’S PRACTICE
Karachentsev, Y. I., Kozakov, O., Romanova, I. P., & Кравчун, Н. А. (2013) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2013.4.07
Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch14
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_44
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-2
Treating Type 2 Diabetes Mellitus
Migdal, A. L., & Abrahamson, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-1
Glucose control: Non-insulin therapies
(2014) · South African Family Practice · doi:10.1080/20786204.2014.10844579
Effect of Immortal Time Bias Controlled Metformin for Cancer Development in Diabetic Patients
Seo, H. J. (2022) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2022.22.1.40
Rogers, N. E. (2016) · International Society of Hair Restoration Surgery · doi:10.33589/26.3.0116
Glucose Control: non-insulin therapies*
The Society for Endocrinology Metabolism and Diabetes of South Africa (2018) · South African Family Practice · doi:10.4102/safp.v60i1.4821
Akter, N. (2021) · BIRDEM Medical Journal · doi:10.3329/birdem.v11i2.53125
Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose
Cao, L., Li, J., Wu, H., Liu, G. J., Dong, B. R., & Lü, Q. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009989.pub2
REMOTE RESULTS OF USING THREE-HYPOGLYCEMIC THERAPY IN PATIENTS WITH TYPE 2 DIABETES
Кравчун, Н. А., Kazakov, A., Romanova, I. P., & Chernyavska, I. V. (2012) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2012.4.11
Pioglitazona y su relación con el cáncer de vejiga. Revisión sistemática
Brito, M. A. C., Brito, M. A. C., Espín, F. F. C., & Ortiz, F. B. G. (2024) · Revista Mexicana de Urología · doi:10.48193/8s9rt103
Safety Warnings on the Same Harmful Effects of Medicines: A Comparison of Four National Regulators
Perry, L. T., Bhasale, A. L., Hooimeyer, A., McEwin, E. J., Mohammad, A., & Mintzes, B. J. (2025) · Pharmaceutical Medicine · doi:10.1007/s40290-025-00573-y
Vitamin E as a Therapeutic Agent for NAFLD: A Systematic Review of Randomized Controlled Trials
Liu, C., Bai, Z., & Cheng, J. (2025) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20251304.12
Pawar, A. D., Rohile, S. B., & D., S. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29628
Kubota, K. (2013) · Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku · doi:10.3820/jjpe.18.41
Anti-diabetic effects of oleanolic acid and matrine
Zeng, X. (2014) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27351540
Hiebeler, M. (2020) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.25860
Ο ρόλος της διατροφής στην παθογένεση του καρκίνου της ουροδόχου κύστης
Μπακόλα, Χ. (2019) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.7730
Cistectomia radicale e neovescica ortotopica nella donna: risultati oncologici e funzionali
TESI, L. (2013) · Electronic Theses and Dissertations Repository (University of Pisa)
MANICA, M. (2016) · Electronic Theses and Dissertations Repository (University of Pisa)
Genetic engineering of the skeletal muscle to counteract insulin resistance and obesity
Lecha, C. R., & Molecular, U. A. D. B. D. D. B. I. D. B. (2014) · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona)
بررسی شیوع سرطان مثانه در انتهای سال ۱۳۹۶ و عوامل خطر مرتبط با این سرطان در استان کرمان
Abdollahi Nia, Z. (2021) · Research Information System of Ardabil University of Medical Sciences (Ardabil University of Medical Sciences)
Blöcher, R. (2016) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt)
Bazı geleneksel tıbbi bitkilerin antidiyabetik etkinliğinin ve etki mekanizmasının aydınlatılması
Çam, M. E. (2017) · Dspace Repository (Marmara Üniversitesi)
Abdollahi Nia, Z. (2021) · Research Information System of Ardabil University of Medical Sciences (Ardabil University of Medical Sciences)
Okutucu, G. (2015) · Dspace Repository (Marmara Üniversitesi)
KALAYCI, M. (2013) · DSpace - FIRAT (Fırat University)
SCIVITTARO, F. (2015) · Electronic Theses and Dissertations Repository (University of Pisa)
Hosalli, N., Jalageri, M. I., & Bandargal3, V. (2025) · Journal of Carcinogenesis · doi:10.64149/j.carcinog.24.6s.132-145
Rôle dual de PPARγ dans les tumeurs de la vessie
Coutos-Thévenot, L. (2019) · theses.fr (ABES) · doi:10.70675/722cf0a1z8100z456dzaae3z4e9a5b9eba5b
Mécanisme moléculaires du rôle protumorigénique de PPARgamma et RXRalpha dans les cancers de vessie
Beji, S. (2020) · theses.fr (ABES) · doi:10.70675/99f394a9zdd8bz4cb8z8348z6ada0a583d32
Steevens, N., Keller, K., Broughton, L., Stegura, C., Beck, T. C., & Valdebran, M. (2026) · Journal of Visualized Experiments · doi:10.3791/70280
Lei, D., Wu, J.-H., Zeng, X.-H., Xu, R., Zheng, S.-S., Zhu, X.-J., & Jian-a, Y. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.05.024
Freude, A. (2025) · Gutenberg Open Science · doi:10.25358/openscience-14924
Nie, L., Zou, X., Liu, H. F., Peng, Y., Li, J., Jing, T., Wang, H. Y., & Wang, D. (2026) · Discover Oncology · doi:10.1007/s12672-026-05599-5
Metadata
- Authors
- Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L.
- Affiliations
- University of Pennsylvania (US)
- Kaiser Permanente (US)
- Corresponding author
- Lewis, James D.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 916-922
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3064051
- OpenAlex
- W2121264929
- Cited by
- 625
- References
- 24
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 19 · 2021: 18 · 2020: 25 · 2019: 21 · 2018: 29 · 2017: 35 · 2016: 55 · 2015: 58 · 2014: 79 · 2013: 90 · 2012: 119
- FWCI
- 42.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, diabetes mellitus, drug safety, cancer risk, treatment duration, thiazolidinediones, antidiabetic drugs, early-stage cancer detection
- MeSH terms
- Pioglitazone, Adult, Aged, Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Middle Aged, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.